A recently published review in the journal 'Expert Review of Neurotherapeutics' considered the placebo-controlled randomized, double-blind studies using Erenumab for migraine prevention.

Erenumab is a monoclonal antibody (mAb), which mainly blocks the calcitonin gene-related peptide (GGRP) receptor. Lucas Hendrick Overeem et al. searched the articles written in English on PubMed using the terms; CGRP receptor, episodic and chronic migraine, migraine prophylaxis and prevention, CGRP, CGRP receptor antagonist, erenumab, trigeminal nerve and, treatment failures.  As the primary endpoints in Phase II and III preventive episodic migraine trials have been reached successfully, and hence, there were multiple secondary endpoints. The monthly subcutaneous injections of either erenumab 70 mg or 140 mg decreased the mean monthly migraine days (MMDs) after 3 and 6 months significantly higher than placebo when compared to baseline values. The onset of action occurred within the first week. Around 50% of patients experienced at least a 50% reduction of MMDs. Many patient-reported outcome measures portrayed an enhanced quality of life with erenumab. Efficacy in a prior preventive treatment failure population has been revealed due to this antibody. The tolerability of erenumab has been found to be good as observed from low dropout rates in all clinical trials. No particular group or type of adverse events was found within the first year of the treatment.

"Erenumab will undoubtedly be further investigated in the future for cluster headaches and probably beyond", noted the study authors.